Ryan McDonald

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.

Lurbinectedin in combination with pembrolizumab in the second-line shows promising safety and efficacy in relapsed small cell lung cancer

With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.

Lenvatinib in combination with pembrolizumab demonstrated clinical benefit in patients with advanced renal cell carcinoma regardless of their biomarker status.

Venetoclax dosed at either 400 mg or 800 mg in combination with daratumumab and dexamethasone showed promising preliminary results in a phase 1/2 study.

Data from the phase 2 VISION trial showed that restarting treatment with the combination was feasible in a select group of patients who initially had undetectable MRD after 15 cycles of treatment.

In an epidemiological study, a 24-month lymphedema rate of 39.4% was the highest incidence of lymphedema observed among Black women.

Clinically effective results in a group of patients with HRD-positive, chemotherapy-naïve metastatic castration resistant prostate cancer was induced with nivolumab plus rucaparib.

Despite the several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.

Interim results from the phase 3 ALPINE trial suggest that treatment with zanubrutinib may be superior to treatment with ibrutinib for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

In newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation.

Increased efficacy was observed with the combination of mosunetuzumab with polatuzumab vedotin in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

One infusion of ciltacabtagene autoleucel lead to early and deep responses in a cohort of patients previously treated for relapsed/refractory multiple myeloma, according to findings the phase 2 CARTITUDE-2 study.

Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.

In patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy, the addition of the anti–fucosyl-GM1 monoclonal antibody, BMS-986012 to nivolumab demonstrated promising results in a phase 1/2 study.

The addition of pembrolizumab and trastuzumab to the combination cisplatin plus capecitabine was able to effectively treat HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of PD-L1 expression in the phase 1b/2 PANTHERA trial.

Patients with radiation-associated breast angiosarcoma may have an effective treatment option with the combination of oral paclitaxel with encequidar.

Data from a 29-practice consortium shows that oncologists tend to under-recognize substantial symptoms among patients with breast cancer receiving radiotherapy after they have undergone a lumpectomy, according to a presentation during the 2020 San Antonio Breast Cancer Symposium. The data underscore a need for improvement in symptom detection.

Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.

The autologous anti-CD19 CAR T-cell therapy KTE-X19 had a pharmacodynamic profile associated with efficacy and treatment-related neurological events in patients with relapsed/refractory mantle cell lymphoma, according to data from the ZUMA-2 clinical trial.